Vetter Pharma International GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vetter Development Service: Filling your clinical development needs

Vetter Development Service supports your drug-development projects, from inception to market launch. Our Chicago facility, along with our existing sites, provides clinical manufacturing from preclinical development through Phase II, with scale-up and transfer to our commercial manufacturing facilities.

Early planning can help save costs: Together, we work with you to develop the appropriate delivery system for your drug, starting in early development. In addition to matching all components to your product’s specifications, we replicate commercial manufacturing processes in our laboratories, which can prevent surprises when your drug reaches market production. Once products reach Phase III, we provide seamless transfer to our large-scale manufacturing facilities in Europe for late-stage and commercial production. Simultaneous activities, coupled with expertise and foresight, reduce time to market. To help prolong your success, Vetter also offers support on product lifecycle management, which ideally begins in the preclinical phase and becomes an integral part of the drug development process.

A leading manufacturer of aseptically prefilled drug-delivery systems, Vetter offers extensive experience with a broad array of substances, including monoclonal antibodies, peptides, interferons and vaccines.

Vetter Development Service provides:

  • Formulation support
  • Process development
  • Clinical trial manufacturing
  • Analytical service
  • Regulatory support

Website: www.vetter-pharma.com
E-mail: info@vetter-pharma.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here